Immunome Inc (IMNM) Stock AnalysisIMNMStock AnalysisImmunome Inc

Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Immunome Inc is a good buy right now due to its promising clinical data and strong cash position. The current price is $27.57, and analysts have set a price target of up to $37, indicating potential upside of 34%. Additionally, the company has a cash reserve of $582.7 million, which is expected to fund operations into 2028, mitigating short-term financial risks. However, the main risk is the negative net income, which stands at -$73.1 million for Q2 2026, indicating ongoing losses that investors should monitor closely.